- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of nivolumab ( Opdivo ) and ...
The Food and Drug Administration (FDA) has revised the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) t...
Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clo...
Version 1.2022 of the National Comprehensive Cancer Network (NCCN) guidelines now include ripretinib ( Qinlock ) as a category 1 fourth-line tr...
Treatment with RP1 and nivolumab ( Opdivo ) resulted in promising antitumor responses and a well-tolerated safety profile in a population of pa...
The FDA today approved the use of Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) for a broader range of patients with heart failu...
New agents for rare cancers make up approximately 35% of drugs in the pipeline for all rare diseases, according to a report from the Pharmaceutic...
The addition of atezolizumab ( Tecentriq ) to neoadjuvant gemcitabine and cisplatin (GC) generated a high rate of non–muscle-invasive downstagi...
Treatment with lenvatinib ( Lenvima ) plus pembrolizumab ( Keytruda ) led to a significantly improved survival benefit for patients with adva...
The Food and Drug Administration (FDA) has approved Purdue Pharma’s Nalmefene Hydrochloride Injection for the complete or partial reversal of opi...
